Table 39, Clinical Outcomes for the Long-Term Extension Study - Ustekinumab (Stelara)

	PLA SC^a	UST
Randomized patients in clinical response at week 44^c
N	▬	▬	▬	▬
Clinical remission, n (%)
Week 44	▬	▬	▬	▬
Week 92^c,^d	▬	▬	▬	▬
Steroid-free clinical remission, n (%)
Week 92^c,^d,^e	▬	▬	▬	▬
	PLA SC^f	90 mg SC q.12.w.^g	90 mg SC q.8.w.^h
Non-randomized patients in clinical response at week 44^c
N	▬	▬	▬	-
Clinical remission, n (%)
Week 44	▬	▬	▬	-
Week 92	▬	▬	▬	-
Steroid-free clinical remission, n (%)
Week 92^c,^d,^e	▬	▬	▬	-

PLA SC^a

UST

90 mg SC q.12.w.^a

90 mg SC q.8.w.^a

90 mg SC q.8.w. prior dosage adjustment^b

Randomized patients in clinical response at week 44^c

▬

Clinical remission, n (%)

Week 44

▬

Week 92^c,^d

▬

Steroid-free clinical remission, n (%)

Week 92^c,^d,^e

▬

PLA SC^f

90 mg SC q.12.w.^g

90 mg SC q.8.w.^h

Non-randomized patients in clinical response at week 44^c

▬

Clinical remission, n (%)

Week 44

▬

Week 92

▬

Steroid-free clinical remission, n (%)

Week 92^c,^d,^e

▬

From: APPENDIX 6, SUMMARY OF THE IM-UNITI EXTENSION STUDY

Ustekinumab (Stelara) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 39Clinical Outcomes for the Long-Term Extension Study